Vitiligo: concise evidence based guidelines on diagnosis and management
暂无分享,去创建一个
D. Gawkrodger | A. Ormerod | A. Anstey | M. Whitton | M. J. Watts | J. Ingham | L. Shaw | I. Mauri-Sole | K. Young
[1] R. Spritz,et al. Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8. , 2010, The Journal of investigative dermatology.
[2] J. D. Rosso,et al. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo , 2010 .
[3] D. Gawkrodger,et al. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. , 2010, The Journal of investigative dermatology.
[4] R. Wittal,et al. A randomized, double‐blinded, placebo‐controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo , 2009, The British journal of dermatology.
[5] M J Watts,et al. Guideline for the diagnosis and management of vitiligo , 2008, The British journal of dermatology.
[6] J. Hawk,et al. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. , 2007, Archives of dermatology.
[7] J. Naeyaert,et al. Topical pimecrolimus in the treatment of vitiligo. , 2007, European journal of dermatology : EJD.
[8] K. Saedi,et al. The efficacy of combined PUVA and low‐dose azathioprine for early and enhanced repigmentation in vitiligo patients , 2006, The Journal of dermatological treatment.
[9] D. Ashcroft,et al. Interventions for vitiligo. , 2006, The Cochrane database of systematic reviews.
[10] D. Gawkrodger,et al. Vitiligo presentation in adults , 2005, Clinical and experimental dermatology.
[11] J. Naeyaert,et al. Quality of Life and Stigmatization Profile in a Cohort of Vitiligo Patients and Effect of the Use of Camouflage , 2005, Dermatology.
[12] Y. Saral,et al. Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. , 2005, European journal of dermatology : EJD.
[13] N. Fallah,et al. What patients with vitiligo believe about their condition , 2004, International journal of dermatology.
[14] A. Ehlers,et al. Measuring adjustment to chronic skin disorders: validation of a self-report measure. , 2003, Psychological assessment.
[15] B. Moncada,et al. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. , 2003, Archives of Dermatology.
[16] S. Mattoo,et al. Psychiatric morbidity in vitiligo: prevalence and correlates in India , 2002, Journal of the European Academy of Dermatology and Venereology : JEADV.
[17] Jonathan A. Smith,et al. Living with vitiligo: dealing with difference. , 2002, British journal of health psychology.
[18] H. Hönigsmann,et al. Oral dexamethasone pulse treatment for vitiligo. , 2001, Journal of the American Academy of Dermatology.
[19] K. Midthjell,et al. Prevalence of thyroid disease, thyroid dysfunction and thyroid peroxidase antibodies in a large, unselected population. The Health Study of Nord-Trondelag (HUNT). , 2000, European journal of endocrinology.
[20] L. Papadopoulos,et al. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. , 1999, The British journal of medical psychology.
[21] W. Westerhof,et al. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. , 1999, Archives of dermatology.
[22] L. Papadopoulos,et al. Psychological factors in cutaneous disease : an overview of research , 1999 .
[23] P. Bossuyt,et al. A systematic review of autologous transplantation methods in vitiligo. , 1998, Archives of dermatology.
[24] W. Westerhof,et al. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. , 1997, Archives of dermatology.
[25] P. Majumder,et al. Recent investigations on vitiligo vulgaris. , 1997, Dermatologic clinics.
[26] J. Wood,et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. , 1995, Dermatology.
[27] P. Majumder,et al. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. , 1994, American journal of human genetics.
[28] R. Clayton. A double‐blind trial of 0.05% clobetasol proprionate in the treatment of vitiligo , 1977, The British journal of dermatology.
[29] E. Kandil. Treatment of vitiligo with O·1% betamethasone 17‐valerate in isopropyl alcohol—a double‐blind trial , 1974 .
[30] E. Kandil. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol--a double-blind trial. , 1974, The British journal of dermatology.